New orally active anticoagulant agents for the prevention and treatment of venous thromboembolism in cancer patients

References

• TrousseauAPhlegmasia alba dolensTrousseauAClinique Medicale de l’Hotel Dieu de ParisParisBalllier1865654712 French
   Google Scholar
• ZwickerJIFurieBCFurieBCancer-associated thrombosisCrit Rev Oncol Hematol200762212613617293122
   PubMed Web of Science ®Google Scholar
• HeitJAMohrDNSilversteinMDPettersonTMO’FallonWMMeltonLJ3rdPredictors of recurrence after deep vein thrombosis and pulmonary embolismArch Intern Med2000160676176810737275
   PubMed Web of Science ®Google Scholar
• BlomJWDoggenCJOsantoSRosendaalFRMalignancies, prothrombotic mutations, and the risk of venous thrombosisJAMA2005293671572215701913
   PubMed Web of Science ®Google Scholar
• ShenVSPollakEWFatal pulmonary embolism in cancer patients: is heparin prophylaxis justified?South Med J19807378418437384840
   PubMed Web of Science ®Google Scholar
• WhiteRHChewHKZhouHIncidence of venous thromboembolism in the year before the diagnosis of cancer in 528,693 adultsArch Intern Med2005165151782178716087828
   PubMed Web of Science ®Google Scholar
• PoliteBNLamontEBAre venous thromboembolic events associated with subsequent breast and colorectal carcinoma diagnoses in the elderly? A case-control study of Medicare beneficiariesCancer2006106492393016411227
   PubMed Web of Science ®Google Scholar
• RanceAEmmerichJGuedjCFiessingerJNOccult cancer in patients with bilateral deep-vein thrombosisLancet19973509089144814499371175
   PubMed Web of Science ®Google Scholar
• SutherlandDEWeitzICLiebmanHAThromboembolic complications of cancer: epidemiology, pathogenesis, diagnosis and treatmentAm J Hematol2003721435212508268
   PubMed Web of Science ®Google Scholar
• LeeAYEpidemiology and management of venous thromboembolism in patients with cancerThromb Res2003110416717214512077
   PubMed Web of Science ®Google Scholar
• MonrealMMunozFJRosaVUpper extremity DVT in oncological patients: analysis of risk factors. Data from the RIETE registryExp Oncol200628324524717080021
   PubMedGoogle Scholar
• ColemanRMacCallumPTreatment and secondary prevention of venous thromboembolism in cancerBr J Cancer2010102Suppl 1S17S2320386545
   PubMedGoogle Scholar
• KahnSRLimWDunnASAmerican College of Chest PhysiciansPrevention of VTE in nonsurgical patients: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice GuidelinesChest2012141Suppl 2e195Se226S22315261
   PubMed Web of Science ®Google Scholar
• KearonCAklEAComerotaAJAmerican College of Chest PhysiciansAntithrombotic therapy for VTE disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice GuidelinesChest2012141Suppl 2e419Se494S22315268
   PubMed Web of Science ®Google Scholar
• GerotziafasGTPapageorgiouCHatmiMSamamaMMElalamyIClinical studies with anticoagulants to improve survival in cancer patientsPathophysiol Haemost Thromb2008363–420421119176993
   PubMed Web of Science ®Google Scholar
• LeeAYThrombosis in cancer: an update on prevention, treatment, and survival benefits of anticoagulantsHematology Am Soc Hematol Educ Program201014414921239784
   PubMed Web of Science ®Google Scholar
• PrandoniPLensingAWPrinsMHResidual venous thrombosis as a predictive factor of recurrent venous thromboembolismAnn Intern Med20021371295596012484710
   PubMed Web of Science ®Google Scholar
• KearonCNatural history of venous thromboembolismCirculation200310723 Suppl 1I22I3012814982
   PubMed Web of Science ®Google Scholar
• GerotziafasGTSamamaMMHeterogeneity of synthetic factor Xa inhibitorsCurr Pharm Des200511303855387616305517
   PubMed Web of Science ®Google Scholar
• Gómez-OutesASuárez-GeaMLLecumberriRRochaEPozo-HernándezCVargas-CastrillónENew parenteral anticoagulants in developmentTher Adv Cardiovasc Dis201151335921045018
   PubMedGoogle Scholar
• LassenMRLauxVEmergence of new oral antithrombotics: a critical appraisal of their clinical potentialVasc Health Risk Manag2008461373138619337550
   PubMedGoogle Scholar
• SamamaMMGerotziafasGTNewer anticoagulants in 2009J Thromb Thrombolysis20102919210419838770
   PubMed Web of Science ®Google Scholar
• DenasGPengoVEmerging anticoagulantsExpert Opin Emerg Drugs2011161314421352068
   PubMed Web of Science ®Google Scholar
• UferMComparative efficacy and safety of the novel oral anticoagulants dabigatran, rivaroxaban and apixaban in preclinical and clinical developmentThromb Haemost2010103357258520135071
   PubMed Web of Science ®Google Scholar
• CohenAInvestigators of the MAGELLAN trialRivaroxaban compared with enoxaparin for the prevention of venous thromboembolism in acutely ill medical patients60th meeting of the American College of CardiologyApr 2011New Orleans, USA
   Google Scholar
• GoldhaberSZLeizoroviczAKakkarAKApixaban versus enoxaparin for thromboprophylaxis in medically ill patientsN Engl J Med2011365232167217722077144
   PubMed Web of Science ®Google Scholar
• CohenATSpiroTEBullerHRRivaroxaban for thromboprophylaxis in acutely ill medical patientsN Engl J Med2013368651352323388003
   PubMed Web of Science ®Google Scholar
• LevineMNGuCLiebmanHAA randomized phase II trial of apixaban for the prevention of thromboembolism in patients with metastatic cancerJ Thromb Haemost201210580781422409262
   PubMed Web of Science ®Google Scholar
• EINSTEIN InvestigatorsBauersachsRBerkowitzSDBrennerBOral rivaroxaban for symptomatic venous thromboembolismN Engl J Med2010363262499251021128814
   PubMed Web of Science ®Google Scholar
• EINSTEIN-PE InvestigatorsBüllerHRPrinsMHLensinAWOral Rivaroxaban for the Treatment of Symptomatic Pulmonary EmbolismN Engl J Med2012366141287129722449293
   PubMed Web of Science ®Google Scholar
• Botticelli Investigators, Writing CommitteBullerHDeitchmanDPrinsMSegersAEfficacy and safety of the oral direct factor Xa inhibitor apixaban for symptomatic deep vein thrombosis. The Botticelli DVT dose-ranging studyJ Thromb Haemost2008681313131818541000
   PubMed Web of Science ®Google Scholar
• AgnelliGBullerHRCohenAAMPLIFY InvestigatorsOral apixaban for the treatment of acute venous thromboembolismN Engl J Med2013369979980823808982
   PubMed Web of Science ®Google Scholar
• AgnelliGBullerHRCohenAAMPLIFY-EXT InvestigatorsApixaban for extended treatment of venous thromboembolismN Engl J Med2013368869970823216615
   PubMed Web of Science ®Google Scholar
• SchulmanSKearonCKakkarAKDabigatran versus warfarin in the treatment of acute venous thromboembolismN Engl J Med2009361242342235219966341
   PubMed Web of Science ®Google Scholar
• SchulmanSKakkarAKSchellongSMA randomized trial of dabigatran versus warfarin in the treatment of acute venous thromboembolism (RE-COVER II)53rd ASH Annual Meeting and ExpositionDecember 10–13, 2011San Diego
   Google Scholar
• GerotziafasGTBaccoucheHSassiMOptimisation of the assays for the measurement of clotting factor activity in the presence of rivaroxabanThromb Res2012129110110322000405
   PubMed Web of Science ®Google Scholar
• SamamaMMGuinetCLaboratory assessment of new anticoagulantsClin Chem Lab Med201149576177221288169
   PubMed Web of Science ®Google Scholar
• GerotziafasGTGaleaVMbembaETissue factor over-expression by human pancreatic cancer cells BXPC3 is related to higher prothrombotic potential as compared to breast cancer cells MCF7Thromb Res2012129677978621917301
   PubMed Web of Science ®Google Scholar
• BorsigLAntimetastatic activities of heparins and modified heparins. Experimental evidenceThromb Res2010125Suppl 2S66S7120434009
   PubMedGoogle Scholar
• MousaSAPetersenLJAnti-cancer properties of low-molecular-weight heparin: preclinical evidenceThromb Haemost2009102225826719652876
   PubMed Web of Science ®Google Scholar
• FalangaAMarchettiMHeparin in tumor progression and metastatic disseminationSemin Thromb Hemost200733768869418000796
   PubMed Web of Science ®Google Scholar